Fibroblast growth factor 1 (FGF1) has recently emerged as a potentially safe candidate to restore euglycaemia in type 2 diabetes mellitus. Here, Evans and colleagues discuss mechanisms by which central injection of FGF1 can improve central glucose sensing and peripheral glucose uptake, the neuronal circuits involved and therapeutic considerations for translating these findings to the clinic.
- Emanuel Gasser
- Christopher P. Moutos
- Ronald M. Evans
